Search Within

Genitourinary Oncology Service

  1. "David Aggen"
Formats
  1. Meeting Abstract (45)
  2. Journal Article (10)
  3. Editorial (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (60)
  2. Hematologic Malignancies, Division of (60)
  3. Solid Tumor Oncology Division (60)
  4. Hematology-Oncology Fellows (43)
  5. Weinberg Fellows (43)
  6. Graduate Medical Education (38)

More Groups

People
  1. David Aggen (60)
  2. Jonathan Rosenberg (31)
  3. Gopakumar Iyer (29)
  4. Dean Bajorin (26)
  5. Samuel Funt (26)
  6. Min Yuen Teo (25)

More People

Years
  1. 2025 (9)
  2. 2024 (17)
  3. 2023 (12)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (4)
  3. Cancer Research (3)
  4. European Urology (3)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. American Association for Cancer Research (7)
  3. Biomed Central Ltd (3)
  4. Elsevier Science, Inc. (3)
  5. Elsevier Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported experience with an immunotherapy telehealth platform
    Meeting Abstract

    Daly, R. M.; Malling, C.; Dagostino, A.; Bange, E. M.; Preeshagul, I. R.; Aggen, D. H.; Carlo, M.; Chen, M. F.; Eng, J.; Ng, K. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Correlation of NECTIN4 amplification and expression with response to enfortumab vedotin (EV) treatment in locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Yol, C.; Irawan, H.; Sternschuss, M.; Gupta, A.; Bent, E.; Basar, M.; Chen, J. F.; Sarungbam, J.; Chen, Y. B.; Gopalan, A.; more...
    Laboratory Investigation (2025)

    Fulltext@MSK | Save
  • Transcriptional analysis of bladder cancer histologic subtypes reveals novel drug target heterogeneity
    Meeting Abstract

    Tallman, J. E.; Kuo, F.; Koll, F.; Alam, S. M.; Basar, M.; Luo, J.; Gao, S. P.; Tang, X.; Yol, C.; Gokturk, G.; more...
    Urologic Oncology: Seminars and Original Investigations (2025)

    Fulltext@MSK | Save
  • Molecular heterogeneity and immune infiltration drive clinical outcomes in upper tract urothelial carcinoma
    Journal Article

    Kim, K.; Alam, S. M.; Kuo, F.; Chen, Z.; Yip, W.; Katims, A. B.; Chu, C.; Lenis, A. T.; Hu, W.; Gokturk Ozcan, G.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Next-generation sequencing for HLA genotype screening and matching to HLA-restricted therapies
    Research Letter

    Gormally, M. V.; Chen, M. F.; Noronha, A. M.; Panageas, K.; Reynolds, M.; Kohlasch, K.; Novak, B.; Kee-Velez, T.; Clarke, N.; Eubank, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save